Published in final edited form as:

Urology. 2019 February ; 124: 168–173. doi:10.1016/j.urology.2018.09.018.

Immunogenic Heterogeneity of Renal Cell Carcinoma with Venous Tumor Thrombus

Michael A. Liss, Yidong Chen, Ronald Rodriguez, Deepak Pruthi, Teresa Johnson-Pais, Hanzhang Wang, Ahmed Mansour, and Dharam Kaushik

Department of Urology, University of Texas Health San Antonio

Department of Cell and Molecular Biology, University of Texas Health San Antonio

Department of Epidemiology and Biostatistics, University of Texas Health San Antonio

Greehey Children's Cancer Research Institute, University of Texas Health San Antonio

Abstract

Objective: To perform immune-cell enumeration and PD-L1 expression in clear cell renal cell carcinoma (cc-RCC) with tumor thrombus (TT) to guide therapeutic decisions.

Methods: After obtaining IRB approval and surgical consent, six patients underwent radical nephrectomy (RN) with venous tumor thrombectomy. We utilized RNA Sequencing to obtain RNAseq expression profiles. Computational calculation and enumeration of immune cells were performed using CIBERSORT, xCell, and ingenuity pathway analysis (IPA) software. Statistical assessment was conducted using a t-test, chi-square, ANOVA and Spearman rank correlations using SPSS v21.

Results: We observed a higher proportion of M1 macrophages in the primary tumor and tumor thrombus, while we noted no difference in M2 macrophages despite M2 representing a high number in thrombus samples. (ANOVA, $p=0.032$, and $p=0.89$, respectively). Validation with xCell and IPA analysis showed a high involvement of macrophages. We observed a higher number of M1 macrophages (CIBERSORT mean 0.11 vs. 0.03, $p<0.01$) and (non-activated) resting NK cells (0.077 vs. 0.017, $p=0.02$) associated PD-L1 high expression of the primary tumor. PDL1 expression was variable without differences in tumor stage, level, or immune cell detection. We observed an inverse correlation of mean platelet volume (MPV) with PD-L1 expression within the primary tumor (Spearman, -0.89 , $p=0.02$) and the TT (Spearman, -0.77 , $p=0.07$).

Conclusion: Renal tumor thrombus has higher levels of M1 macrophages that could be utilized as additional targets for future drug development. The PD-L1 expression on ccRCC biopsy may not represent its corresponding TT. Future studies are needed to confirm MPV as a potential blood-based biomarker for PD-L1 expression in RCC.

Corresponding Author; Michael Liss MD, MAS, FACS, Assistant Professor, Department of Urology, UT Health San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, liss@uthscsa.edu, Tel: 210-567-5643.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Kidney Cancer; Renal Cancer; Thrombus; Immunotherapy; PDL; Biomarker

Introduction

There is more than 62,000 new renal cell carcinoma (RCC) diagnosed each year in the United States.¹ The most common renal cancer is of the clear cell RCC (ccRCC). While rare, it is one of a few tumors that extends in the venous system and can propagate to the atrium of the heart. RCC can invade into the inferior vena cava in 4–10% of renal cancer cases.^{2, 3} The five-year overall survival can range from 32–69% depending on several factors including metastasis at the time of diagnosis.^{4–7} Reese et al. reported the natural history of untreated tumor thrombus and noted 87% of these patients (n=297) died of renal cancer with a median survival of 5 months.⁸ The tumor thrombus level does not affect disease-specific survival but can have a tremendous impact on surgical complexity, which remains the standard treatment modality.^{9, 10}

Neoadjuvant chemotherapy has been utilized in RCC to reduce the size of the tumor and improve surgical morbidity. Partial response rates average around 40% in small series of neoadjuvant therapy for tumor thrombus mainly with tyrosine kinase inhibitors (TKIs).¹¹ However, no studies have demonstrated a significant reduction in thrombus size required to change extensively change surgical management.¹²

No definitive data to date shows that targeting immune checkpoint inhibitors can reduce renal tumor thrombus level. However, due to the significant tumor heterogeneity of RCC relevant biomarkers have been elusive. Herein, we seek to evaluate differences in renal tumor thrombus cell using expression profiles compared to the primary tumor and adjacent normal tissue to determine the immune composition of tumor thrombus and potential associated biomarkers.

Methods

Population:

We prospectively identified six patients and consented before nephrectomy and thrombectomy for fresh tumor collection. None of the patients received neoadjuvant chemotherapy. We collected tissue prospectively by flash frozen processing for preservation. Additionally, we sent the specimen for standard pathological processing and recording. We obtained demographic and standard laboratory values before surgery and recorded cancer recurrence and clinical outcomes.

RNA-Seq:

We performed sequencing with an Illumina HiSeq 3000 system using 100bp paired-end protocol following the manufacturer's protocol to attain mRNAs of all samples. The obtained short sequence reads were aligned to UCSC human genome build hg19 using

TopHat2.¹³ The bam files from alignment were processed using HTSeq-count to compute the counts per gene in all samples.¹⁴

Bioinformatics:

CIBERSORT: Using RNA expression data, we utilized the CIBERSORT program (<https://cibersort.stanford.edu/>) that provides an enumeration of immune cells in tumor samples based on RNA expression profile.¹⁵ CIBERSORT is a method to enumerate immune subsets using RNA-Seq without limitations of immunohistochemistry or flow cytometry. CIBERSORT uses an alternative approach to acquire aggregative high dimensional data from tumor cellular mixtures and computationally infer the cellular components from prior knowledge of expression profiles from purified leukocyte subsets.¹⁶

xCell Analysis: We performed xCell analysis to validate the immune cell heterogeneity findings from the CIBERSORT program of our collected ccRCC samples.¹⁷ We submitted the gene expression level in RPKM (Reads Per Kilobase Million) unit obtained from RNA-seq to the xCell website (xcell.ucsf.edu) and each tissue's enrichment score to evaluate p-values. P-value < 0.05 is considered significant enrichment.

Ingenuity pathway analysis: Ingenuity Pathway Analysis (IPA) was performed on 26 differentially expressed genes identified by comparison between ccRCC tumor samples vs. tumor thrombus using edgeR algorithms.¹⁸ We identified networks of potentially interacting proteins and placed into node-edge diagrams comprised of focused genes (upregulated: red; down-regulated: green) detected by RNA-seq and other interacting molecules (gray or white). We also plotted the expression of various gene networks and canonical pathways and their corresponding enrichment p-values to overlap ratios.

Statistical analysis:

The Programmed death-ligand 1 (PD-L1) expression profile cut-off was a two-fold change over adjacent normal kidney tissue. We analyzed the primary tumor and the tumor thrombus against adjacent normal. We utilized the student's t-test for continuous variables and the chi-squared test for categorical variables. We performed correlations with the Spearman test due to the small numbers of samples.

Results

Demographics:

We identify variability in PD-L1 expression in six patients with renal tumor thrombus. We display the patient demographics in Table 1. The PD-L1 expression did not correlate any demographic information (all $P > 0.05$). Figure 1 displays imaging from 6 patients who underwent nephrectomy and tumor thrombectomy. We displayed the PD-L1 expression profiles and immune cell enumeration below each clinical image of the tumor thrombus.

Numeration of Immune cell profile:

We identified that there are differences to include a higher number of M1 macrophages (CIBERSORT mean 0.11 vs. 0.03, $p < 0.01$) and (non-activated) resting NK cells (0.077 vs.

0.017, $p=0.02$) in PD-L1 high expression of the primary tumor, respectively. However, when applying this high PD-L1 expression within the tumor thrombus compared to adjacent normal two subjects were unable to identify any CIBERSORT immune cell variables that were significant. We then examined normal adjacent, primary tumor, and tumor thrombus; we only detected M1 macrophages that are distinctly different (higher) in the primary tumor and tumor thrombus. We identified no difference in M2 macrophages (ANOVA, $p=0.032$, and $p=0.89$, respectively, Supplemental Figure 1a and 1b).

Confirmation of M1/M2 Polarization:

We confirmed M1 and M2 macrophages with individual marker genes to validate the CIBERSORT data. We selected CSF1 (Colony-stimulating factor 1, also called macrophage colony-stimulating factor 1) and CD86 as M1 markers (Supplemental Figure 2). We used the paired t-test for statistical comparison and noted significance for both markers. For M2, we selected MRC1 (or CD206) and CD163 as markers. CD206 is significant between normal renal tissue and local tumor. However, we noted an association between CD163 and cancer in the kidney rather than the tumor thrombus (2nd row).

Validation of Enumeration and IPA analysis:

We performed two levels of bioinformatic validation of enumeration. First, to confirm CIBERSORT analysis, we conducted a study using the xCell platform to establish the presence of various cell types (Figure 2). In this figure, we noted the dominant representation of macrophages, while T cells are less represented in the tumors. There is some representation from T helper cells. We identified networks of potentially interacting proteins and placed into node-edge diagrams comprised of focused genes (Figure 3a). We also examined enriched canonical pathways represented in a bar graph (Figure 3b, top 10 pathways). Three pathways emerged as most important: agranulocyte adhesion and diapedesis differential regulation of cytokine production, differential regulation of cytokine prediction in intestinal epithelial cells by IL17-A and IL17F, and glutathione-mediated detoxification.

PD-L1 Expression:

Examining tumor compared to adjacent normal using a two-fold change or higher cut off from the normal adjacent PD-L1 expression, we noted three tumors (ID# 0,5,7) were of high PD-L1 expression, and three others (ID# 1,8,9) were of low PD-L1 expression. Of note, there was variability in two subjects that showed the primary tumor and thrombus could have different PD-L1 expression. Subject # 5 had 2.9-fold higher expression in the primary tumor but low expression in the tumor thrombus. Subject #8 had low expression in the primary tumor but increased in the tumor thrombus (2.7-fold expression). Taking these into account, the tumor thrombus PD-L1 expression groups (high vs. low) in the tumor thrombus did not show any differences in immune cell detection.

Mean Platelet Volume:

The mean platelet volume did have an inverse correlation with PD-L1 expression within the primary tumor (Spearman, -0.89 , $p=0.02$, Supplemental Figure 2a) and near significance

with PD-L1 expression within the tumor thrombus (Spearman, -0.77 , $p=0.07$, Supplemental Figure 2b).

Discussion

Our findings indicate that the inflammatory processes inside ccRCC with tumor thrombus (TT) are complex varying between patients and within the primary tumor of the same patient. A consistent theme regarding cell enumeration is the presence of inflammatory macrophages in higher proportions in the tumor thrombus. Unfortunately, PD-L1 expression was not consistent and renal mass biopsy may not reflect PD-L1 expression within the TT. However, mean platelet volume (MPV) may be a possible biomarker regarding PD-L1 expression within TT. Further studies are required to confirm if MPV would predict PD-L1 inhibitor response. Recently, a low MPV was associated with adverse renal cancer outcomes and may indicate a high-risk group for which PD-L1 inhibition may provide greater benefit.¹⁹

Our primary aim was to investigate the types of cells predominating in tumor thrombus compared to the renal tumor and adjacent normal tissue, as well as, to investigate the PD-L1 expression of ccRCC. The significance of PD-L1 expression in different immune cell subpopulations in the tumor microenvironment remains poorly understood in ccRCC. Neoadjuvant studies have shown partial responses but only rarely does a mammalian target of rapamycin (mTOR) or Tyrosine kinase inhibitor (TKI) inhibition cause dramatic reductions in tumor thrombus size to improve surgical resection and morbidity (approximately 12%).²⁰ RCC is known for its genomic complexity and high mutational burden. Therefore, the presence of complex genomic heterogeneity and a wide range of mutational load in RCC may predict better responses to recently approved checkpoint inhibitors in patients with RCC with tumor thrombus. The physician may utilize checkpoint inhibitors as newer medications to attempt to reduce renal thrombus size. Unfortunately, our data speak to the complexity of the immune system and the heterogeneity of renal cancer. In Figure 1, we illustrate the various tumor thrombus and their respective PD-L1 expression profiles. It is unknown if immunohistochemistry of the tumor would provide helpful information regarding potential responders. However, it is likely that only a small piece of the primary tumor would be biopsied and not the tumor thrombus. Therefore, a renal mass biopsy may not provide accurate information as a PD-L1 biomarker for therapeutic response.

Additionally, we utilized the CIBERSORT software program to provide an inflammatory cell overview of the types of immune cells that population the primary tumor and tumor thrombus. The most abundant immune cells in thrombus were M2 Macrophages and resting (non-activated) CD4 T cells. Usually, M1 macrophages are considered inflammatory (anti-tumor); whereas, M2 macrophages are believed to be more anti-inflammatory and tumor promoting. However, current literature has questioned the simplification of complex macrophage processes.²¹ After testing all 22 immune cells in the CIBERSORT profile, we only identified differences in M1 Macrophage across normal adjacent, primary tumor, and tumor thrombus (ANOVA, $p=0.032$). Using an xCell bioinformatics platform for cell type enumeration profiling, we confirmed that macrophages are likely to have a significant role in

renal tumor thrombus based on their overall abundance. Profiling studies in RCC have recently shown increased complexity in the assumption of M1/M2 macrophage profiling. Macrophages will express genes as a mixture of both M1 and M2 genes rather than exhibit traditional phenotypes.²² One could repolarize macrophages in combination with other therapies with mTOR inhibition, which has been shown to modulate the immune system.²³

We used the IPA analysis to explicitly identify particular pathways used in the tumor thrombus compared to the tumor resident in the kidney proper. While we have confirmed there is a large presence of macrophages by cell enumeration; we utilized the IPA program to determine pathways based on our RNAseq expression profiles. We identified that IL1b as a potential primary driver in interconnecting protein pathway networks. IL1b is a pro-inflammatory cytokine utilized by M1 macrophages to induce an inflammatory reaction and recruit other cells; however, when consistently activated can promote tumorigenesis.²⁴

Additionally, diapedesis was identified as the most statistically significant pathway utilized by the tumor. The finding indicates that the tumor cells are not likely bathing in the bloodstream but continue to require migration of immune cells across barriers. IL17 cytokines may allow an autoimmune type reaction to the thrombus enabling thrombus survival and propagation. Lastly, glutathione-mediated detoxification may render a mechanism for the tumor thrombus to handle reactive oxygen species (ROS) and mitigate oxidative damage from internal and external sources to preserve maintenance of tumor function. ROS are free radicals that efficiently react with DNA, RNA, and proteins and in high levels can cause cell death.²⁵ Interestingly, platelets involved in wound repair release ROS to recruit additional platelets and leukocytes and could be an external source of ROS.²⁶ We hypothesize that if platelets are attracted to the tumor, the platelet volume may be a potential biomarker of aggressiveness.

A recently published article by Seles et al. associated a low blood platelet volume with adverse renal cell cancer outcomes.¹⁹ A cut off of 9.5 had the worst prognosis. We identified two patients with this value and both had the highest PD-L1 expression in the tumor and the tumor thrombus. In our correlative studies, we note an inverse relationship of MPV and PD-L1 expression within tumors. MPV is a surrogate marker of platelet activation. Several mechanistic studies have shown that increased platelets facilitate cancer progression and metastasis by promoting angiogenesis.^{27, 28} Given the inverse correlation (Supplemental Figure 2) demonstrated in our research, MPV could be a potential biomarker for PD-L1 expression in the context of a clinical trial.

Limitations of the current study include the low sample size to produce conclusive evidence of PD-L1 expression and inflammatory markers. This study was performed to influence further investigation regarding the types of inflammatory cells compromising the tumor thrombus and could be targeted before surgery. Another limitation is that we did not confirm our bioinformatic findings on inflammatory cells with flow cytometry or immunohistochemistry. Due to the cost of immunohistochemical and pathologic evaluation, we utilized this platform to identify the most promising pathways and cellular interactions to evaluate. Based on this work we have applied for funding to engage in investigations regarding the role of the macrophage and its function in tumor thrombus formation and

propagations. Due to the small sample size, we would not have been able to provide definitive conclusions even if we performed additional confirmatory investigations.

Conclusion

Thrombus has higher levels of M1 macrophages that could be additional targets in renal cancer thrombus. The PD-L1 expression is variable between primary clear cell renal tumors and its corresponding tumor thrombus; therefore, a renal mass biopsy may not provide actionable data regarding the PD-L1 profile of the tumor thrombus. Confirmatory studies should explore macrophage-specific functions in tumor thrombus development and propagation along with MPV as a potential blood-based biomarker for PD-L1 expression in renal cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

RNA sequencing and analysis were made available to this publication by NIH S10 grant 1S10OD021805-01 and CPRIT Core facility award RP160732 (to YC). An NCI Cancer Center also supports the GCCRI Genome Sequencing Facility shared resource grant NCI P30 CA54174.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017;67:7–30. [PubMed: 28055103]
2. Haddad AQ, Wood CG, Abel EJ, et al. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. *The Journal of urology.* 2014;192:1050–1056. [PubMed: 24704115]
3. Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. *The Journal of urology.* 1988;139:1166–1172. [PubMed: 3373579]
4. Ciano G, Manoharan M, Katkooori D, De Los Santos R, Soloway MS. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. *European urology.* 2010;57:667–672. [PubMed: 19560258]
5. Lund L, Jacobsen J, Norgaard M, et al. The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. *The Journal of urology.* 2009;182:35–40; discussion 40. [PubMed: 19450859]
6. Slaton JW, Balbay MD, Levy DA, et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. *Urology.* 1997;50:673–677. [PubMed: 9372873]
7. Wagner B, Patard JJ, Mejean A, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. *European urology.* 2009;55:452–459. [PubMed: 18692951]
8. Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. *Urol Oncol.* 2013;31:1305–1309. [PubMed: 22237466]
9. Skinner DG, Pfister RF, Colvin R. Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. *The Journal of urology.* 1972;107:711–716. [PubMed: 5022528]
10. Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. *Annals of Surgery.* 1989;210:387–392; discussion 392–384. [PubMed: 2774709]

11. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. *Ther Adv Urol*. 2016;8:130–141. [PubMed: 27034725]
12. Cost NG, Delacroix SE, Jr., Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. *European urology*. 2011;59:912–918. [PubMed: 21367518]
13. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol*. 2013;14:R36. [PubMed: 23618408]
14. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015;31:166–169. [PubMed: 25260700]
15. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods*. 2015;12:453–457. [PubMed: 25822800]
16. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods Mol Biol*. 2018;1711:243–259. [PubMed: 29344893]
17. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol*. 2017;18:220. [PubMed: 29141660]
18. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*. 2010;26:139–140. [PubMed: 19910308]
19. Seles M, Posch F, Pichler GP, et al. Blood Platelet Volume Represents a Novel Prognostic Factor in Patients with Nonmetastatic Renal Cell Carcinoma and Improves the Predictive Ability of Established Prognostic Scores. *The Journal of urology*. 2017;198:1247–1252. [PubMed: 28716649]
20. Schrader AJ, Steffens S, Schnoeller TJ, Schrader M, Kuczyk MA. Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? *Int J Urol*. 2012;19:903–907. [PubMed: 22640774]
21. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014;6:13. [PubMed: 24669294]
22. Chittezhath M, Dhillon MK, Lim JY, et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. *Immunity*. 2014;41:815–829. [PubMed: 25453823]
23. Mercurio A, Calavita I, Dugnani E, et al. Rapamycin unbalances the polarization of human macrophages to M1. *Immunology*. 2013;140:179–190. [PubMed: 23710834]
24. Afonina IS, Muller C, Martin SJ, Beyaert R. Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme. *Immunity*. 2015;42:991–1004. [PubMed: 26084020]
25. Miyata Y, Matsuo T, Sagara Y, Ohba K, Ohyama K, Sakai H. A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis. *Int J Mol Sci*. 2017;18.
26. Qiao J, Arthur JF, Gardiner EE, Andrews RK, Zeng L, Xu K. Regulation of platelet activation and thrombus formation by reactive oxygen species. *Redox Biol*. 2018;14:126–130. [PubMed: 28888895]
27. Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG. Cancer and Thrombosis: The Platelet Perspective. *Front Cell Dev Biol*. 2016;4:147. [PubMed: 28105409]
28. Tanriverdi O, Menekse S, Teker F, et al. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). *J BUON*. 2016;21:840–850. [PubMed: 27685904]

Figure 1. Comparison of clinical tumor images, PD-L1 Expression, and CIBERSORT inflammatory cell expression data.

Figure 2: xCell Analysis.

The figure demonstrates each patient number at the top to include the letters N (adjacent normal), T (tumor within the kidney), and TT (tumor Thrombus). The right side of the figure displays 64 cell types, and the boxes represent the differential expression representing the presence of that cell. Each box with the darker staining has a stronger association with the number of cells detected and associated with a stronger p value located in the figure legend at the bottom right of the figure.

Figure 3: Ingenuity pathway analysis. We performed IPA analysis on 26 differentially expressed genes identified from a comparison between ccRCC tumor samples vs. tumor thrombus using edgeR algorithms. **(A)** We identified a network of connected pathways (upregulated = red, down-regulated = green) by RNA-seq and other interacting molecules (gray or white). **(B)** A bar graph displays the top ten pathways.

Table 1:

Demographics

ID*	Age	Ethnicity	Laterality	BMI	Tumor Size(cm)	Stage	Thrombus Level	Fuhrman Grade	DM	HTN	mean platelet volume
5	46	Hispanic	Right	29.1	10.5	T3b, N0, M1	L1	3	Yes	Yes	9.1
7	55	Hispanic	Center	36.7	4	T3a,N0, M0	L0	2	n/a	n/a	10.4
8	39	Hispanic	Right	21.6	6.5	T4,N0, M1	L2	4	Yes	n/a	9.8
9	69	White	Center	35.6	11	T3a,N0, M0	L0	2	Yes	Yes	15.2
0	46	Hispanic	Center		15	T3b,N0, M1	L2	4	n/a	n/a	8.2
1	85	White	Center	26.3	8	T3c,N0, M0	L4	3	No	Yes	10.9

* ID is the last digit from patient ID (e.g TB31325).